ICHIRO Kawada

写真a

Affiliation

Research Centers and Institutes, Health Center Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine (Hiyoshi)

Position

Associate Professor (Non-tenured)

External Links

Career 【 Display / hide

  • 1998.05
    -
    2000.04

    慶應義塾大学医学部, 内科学教室, 研修医

  • 2000.05
    -
    2001.05

    埼玉県立循環器・呼吸器病センター, 内科, 専修医

  • 2001.06
    -
    2002.05

    東京歯科大学市川総合病院, 内科, 助手

  • 2002.06
    -
    2005.06

    慶應義塾大学医学部, 呼吸循環器内科, 助手

  • 2005.07
    -
    2009.12

    日野市立病院, 内科, 主任医員

display all >>

Academic Background 【 Display / hide

  • 1992.04
    -
    1998.03

    慶應義塾大学, 医学部

    University, Graduated

Academic Degrees 【 Display / hide

  • 学士(医学), Keio University, Coursework, 1998.03

  • 博士(医学), Keio University, Dissertation, 2009.02

    非小細胞肺がん患者における上皮成長因子受容体遺伝子変異のRFLP法によるスクリーニング法の確立

Licenses and Qualifications 【 Display / hide

  • 医師免許, 1998.05

  • 日本内科学会 認定内科医, 2002.09

  • 日本内科学会 総合内科専門医, 2006.12

  • 日本内科学会 指導医, 2006.09

  • 日本内科学会 JMECCインストラクター, 2015.12

display all >>

 

Research Areas 【 Display / hide

  • Life Science / Respiratory medicine

 

Books 【 Display / hide

  • インフルエンザ診療マニュアル

    Kawada Ichiro, 南江堂, 2001.01

    Scope: インフルエンザと社会

Papers 【 Display / hide

  • Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

    Shinkai M., Tsushima K., Tanaka S., Hagiwara E., Tarumoto N., Kawada I., Hirai Y., Fujiwara S., Komase Y., Saraya T., Koh H., Kagiyama N., Shimada M., Kanou D., Antoku S., Uchida Y., Tokue Y., Takamori M., Gon Y., Ie K., Yamazaki Y., Harada K., Miyao N., Naka T., Iwata M., Nakagawa A., Hiyama K., Ogawa Y., Shinoda M., Ota S., Hirouchi T., Terada J., Kawano S., Ogura T., Sakurai T., Matsumoto Y., Kunishima H., Kobayashi O., Iwata S.

    Infectious Diseases and Therapy (Infectious Diseases and Therapy)  10 ( 4 ) 2489 - 2509 2021.12

    ISSN  21938229

     View Summary

    Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus. Favipiravir is an orally administrable antiviral drug whose mechanism of action is to selectively inhibit RNA-dependent RNA polymerase. A preliminary trial in COVID-19 patients reported significant improvements across a multitude of clinical parameters, but these findings have not been confirmed in an adequate well-controlled trial. We conducted a randomized, single-blind, placebo-controlled Phase III trial assessing the efficacy and safety of favipiravir in patients with moderate pneumonia not requiring oxygen therapy. Methods: COVID-19 patients with moderate pneumonia (SpO2 ≥ 94%) within 10 days of onset of fever (temperature ≥ 37.5 °C) were assigned to receive either placebo or favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days) in a ratio of 1:2. An adaptive design was used to re-estimate the sample size. The primary endpoint was a composite outcome defined as the time to improvement in temperature, oxygen saturation levels (SpO2), and findings on chest imaging, and recovery to SARS-CoV-2-negative. This endpoint was re-examined by the Central Committee under blinded conditions. Results: A total of 156 patients were randomized. The median time of the primary endpoint was 11.9 days in the favipiravir group and 14.7 days in the placebo group, with a significant difference (p = 0.0136). Favipiravir-treated patients with known risk factors such as obesity or coexisting conditions provided better effects. Furthermore, patients with early-onset in the favipiravir group showed higher odds ratio. No deaths were documented. Although adverse events in the favipiravir group were predominantly transient, the incidence was significantly higher. Conclusions: The results suggested favipiravir may be one of options for moderate COVID-19 pneumonia treatment. However, the risk of adverse events, including hyperuricemia, should be carefully considered. Trial registration: Clinicaltrials.jp number: JapicCTI-205238.

  • Unbiased, comprehensive analysis of Japanese health checkup data reveals a protective effect of light to moderate alcohol consumption on lung function

    Makino K., Shimizu-Hirota R., Goda N., Hashimoto M., Kawada I., Kashiwagi K., Hirota Y., Itoh H., Jinzaki M., Iwao Y., Ko M., Ko S., Takaishi H.

    Scientific Reports (Scientific Reports)  11 ( 1 )  2021.12

     View Summary

    The overall effect of lifestyle habits, such as alcohol consumption, on general health remains controversial and it is important to clarify how such habits affect aging-related health impairments. To discover novel impacts of lifestyle on general health, we employed a mathematical approach to perform a comprehensive, unbiased, cross-sectional analysis of data from 6036 subjects who participated in a Japanese health checkup. Notably, we found that moderate alcohol consumption was positively correlated with lung function, muscle mass, and strength. Health checkup data were collected periodically from the same subjects. These people were light to moderate drinkers who had high health awareness and were basically free of major underlying diseases. We next analyzed 5 years of data from 1765 of these subjects. We found that higher baseline alcohol consumption, as well as increased alcohol intake over 5 years attenuated time-related deterioration of forced vital capacity without affecting total lung volume. This effect was independent of smoking. Our study suggests a possible protective effect of moderate amounts of alcohol on lung function, due to increased muscle mass/strength and forced vital capacity.

  • Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress

    Arai D., Sato T., Nakachi I., Fujisawa D., Takeuchi M., Sato Y., Kawada I., Yasuda H., Ikemura S., Terai H., Nukaga S., Inoue T., Nakamura M., Oyamada Y., Terashima T., Sayama K., Saito F., Sakamaki F., Naoki K., Fukunaga K., Soejima K.

    Oncologist (Oncologist)  26 ( 12 ) e2265 - e2273 2021.12

    ISSN  10837159

     View Summary

    Background: Accurate prognostic understanding in patients with advanced cancer is essential for shared decision making; however, patients may experience psychological burden through knowing the incurable nature of advanced cancer. It has been unclear how their prognostic understanding fluctuates and whether accurate prognostic understanding is associated with psychological distress from the time of diagnosis over time. Materials and Methods: We longitudinally investigated prognostic understanding in 225 patients with newly diagnosed advanced lung cancer at 16 hospitals in Japan until 24 months after diagnosis. We examined associated factors with being consistently accurate in prognostic understanding, especially focusing on its association with psychological well-being. Results: The proportion of patients with an inaccurate prognostic understanding remained approximately 20% over time with the presence of patients with inconsistent understanding. Patients with consistently accurate prognostic understanding showed a significantly lower Emotional Well-Being subscale score at both 3 and 6 months after diagnosis (p =.010 and p =.014, respectively). In multivariate analyses, being consistently accurate in prognostic understanding was significantly associated with female gender and higher lung cancer–specific symptom burden at 3 months (p =.008 and p =.005, respectively) and lower emotional well-being at 6 months (p =.006). Conclusion: Although substantial proportions of patients with advanced lung cancer had inaccurate prognostic understanding from the time of diagnosis over time, patients with consistently accurate prognostic understanding experienced greater psychological burden. Our findings highlight the importance of continuous psychological care and support for patients who understand their severe prognosis accurately. Implications for Practice: This study demonstrated that approximately 20% of patients with advanced lung cancer had an inaccurate understanding about their prognosis, not only at the time of diagnosis but also at the later time points. Being consistently accurate in prognostic understanding was significantly associated with elevated levels of psychological distress. Although accurate prognostic understanding is essential for decision making for treatment and advance care planning, health care providers should be aware of psychological burdens in patients that accept their severe prognosis accurately. Appropriate care and support for such patients are warranted from diagnosis over time.

  • Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: Study protocol

    Nakagawara K., Namkoong H., Terai H., Masaki K., Tanosaki T., Shimamoto K., Lee H., Tanaka H., Okamori S., Kabata H., Chubachi S., Ikemura S., Kamata H., Yasuda H., Kawada I., Ishii M., Ishibashi Y., Harada S., Fujita T., Ito D., Bun S., Tabuchi H., Kanzaki S., Shimizu E., Fukuda K., Yamagami J., Kobayashi K., Hirano T., Inoue T., Kagyo J., Shiomi T., Ohgino K., Sayama K., Otsuka K., Miyao N., Odani T., Oyamada Y., Masuzawa K., Nakayama S., Suzuki Y., Baba R., Nakachi I., Kuwahara N., Ishiguro T., Mashimo S., Minematsu N., Ueda S., Manabe T., Funatsu Y., Koh H., Yoshiyama T., Saito F., Ishioka K., Takahashi S., Nakamura M., Goto A., Harada N., Kusaka Y., Nakano Y., Nishio K., Tateno H., Edahiro R., Takeda Y., Kumanogoh A., Kodama N., Okamoto M., Umeda A., Hagimura K., Sato T., Miyazaki N., Takemura R., Sato Y., Takebayashi T., Nakahara J., Mimura M., Ogawa K., Shimmura S., Negishi K., Tsubota K., Amagai M., Goto R., Ibuka Y., Hasegawa N., Kitagawa Y., Kanai T., Fukunaga K.

    BMJ Open Respiratory Research (BMJ Open Respiratory Research)  8 ( 1 )  2021.11

     View Summary

    Introduction The rapid spread of COVID-19 posed a global burden. Substantial number of people died of the disease in the acute phase of infection. In addition, a significant proportion of patients have been reported to suffer from post-acute phase symptoms, sequelae of COVID-19, which may negatively influence the quality of daily living and/or socioeconomic circumstances of the patients. However, no previous study has comprehensively and objectively assessed the quality of life of patients by using existing international scales. Further, evidence of socioeconomic consequences among patients with COVID-19 is scarce. To address the multidimensional issues from sequelae of COVID-19, evidence from comprehensive surveys beyond clinical perspectives is critical that investigates health, and social determinants of disease progression as well as socioeconomic consequences at a large scale. Methods and analysis In this study, we plan to conduct a nationwide and comprehensive survey for the sequelae of COVID-19 in a total of 1000 patients diagnosed at 27 hospitals throughout Japan. This study will evaluate not only the health-related status of patients from clinical perspectives but also the Health-related Quality of Life (HRQoL) scores, socioeconomic status and consequences to discuss the sequelae of the disease and the related risk factors. The primary endpoint is the frequency of long-term complications of COVID-19 infection. The secondary endpoints are risk factors for progression to sequelae of COVID-19 infection. The study will provide robust and important evidence as a resource to tackle the issues from the sequelae of COVID-19 from the multi-dimensional perspectives. Ethics and dissemination This trial was approved by the Keio University School of Medicine Ethics Committee (20200243, UMIN000042299). The results of this study will be reported at a society meeting or published in a peer-reviewed journal.

  • Cardiac tamponade due to primary malignant pericardial mesothelioma diagnosed with surgical pericardial resection

    Kawakami N., Kawai M., Namkoong H., Arai D., Ueda S., Hamada K., Kawada I., Hasegawa N., Mikami S., Asamura H., Fukunaga K.

    Journal of Cardiology Cases (Journal of Cardiology Cases)  24 ( 4 ) 149 - 152 2021.10

     View Summary

    Primary malignant pericardial mesothelioma is an extremely rare disease. Malignant disease of the pericardium is an infrequent cause of cardiac tamponade. Hence, cardiac tamponade in the context of primary malignant mesothelioma of the pericardium is an uncommon clinical scenario. A 67-year-old male patient, an ex-smoker, complaining of progressive lethargy was referred to a hospital for investigation of persistent pericardial effusion. The pericardial fluid cytology was categorized as class Ⅲ. Thereafter, he was referred to our hospital for further evaluation. Fluorodeoxyglucose (FDG) positron emission tomography (PET) revealed FDG accumulation in the pericardium and mediastinal lymph node. Surgical biopsy of the pericardium was performed through a subxiphoid approach for a definitive diagnosis. Histopathological examination revealed diffuse infiltration of the pericardium by a malignant tumor consisting of epithelioid cells with large round nuclei and prominent nucleoli, arranged in a tubular papillary pattern. Finally, the patient was diagnosed with primary malignant pericardial mesothelioma of epithelioid type. The patient died 6 weeks after admission. This diagnosis must be considered in patients having unexplained massive pericardial effusion. Furthermore, we should consider prompt cytological analysis and FDG PET to arrive rapidly at a definitive diagnosis to administer combination chemotherapy that may provide clinical benefit. <Learning objective: Primary malignant pericardial mesothelioma is a rare disease. Malignant disease of the pericardium is an infrequent cause of cardiac tamponade. Hence, cardiac tamponade in the context of primary malignant mesothelioma of the pericardium is an uncommon clinical scenario. However, this diagnosis must be considered in patients having unexplained massive pericardial effusion. Furthermore, we should consider prompt cytological analysis and fluorodeoxyglucose positron emission tomography to arrive rapidly at a definitive diagnosis to administer combination chemotherapy that may provide clinical benefit.>

display all >>

Reviews, Commentaries, etc. 【 Display / hide

Presentations 【 Display / hide

  • NHBE肺癌発生モデルにおける癌抑制遺伝子、癌遺伝子のメチル化、および脱メチル化の定量的検討

    YAMAGUCHI KAZUHIRO

    第44回日本肺癌学会総会 (東京) , 

    2003.11

    Oral presentation (general)

  • DNAメチル転移酵素3b(DNMT3b)の癌化における重要性

    YAMAGUCHI KAZUHIRO

    第44回日本肺癌学会総会 (東京) , 

    2003.11

    Oral presentation (general)

  • 癌化いおけるde novo DNAメチル転移酵素、DNMT3b1/3b2の機能的差異の検討−実験モデルの確立−

    YAMAGUCHI KAZUHIRO

    第44回日本肺癌学会総会 (東京) , 

    2003.11

    Oral presentation (general)

  • 癌化におけるDNAメチルトランスフェラーゼ(DNMT3b)の重要性

    Soejima Kenzou, Kawada Ichirou, Watanabe Hideo, Fujishima Seitarou, Yamaguchi Kazuhiro

    第43回日本呼吸器学会総会, 

    2003.03

    Oral presentation (general)

  • NHBE肺癌発生モデルにおける癌抑制遺伝子および癌遺伝子プロモーター領域のメチル化,脱メチル化の検討

    Kawada Ichirou, Soejima Kenzou, Watanabe Hideo, Yamaguchi Kazuhiro

    43回日本呼吸器学会総会, 

    2003.03

    Oral presentation (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 悪性胸膜中皮腫におけるMET遺伝子異常の解明と新薬の個別化治療への臨床応用

    2019.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Awards 【 Display / hide

  • 研究奨励賞(Respiratory Research Award)

    2014.11, 第18回東京呼吸病態研究会, 非小細胞肺癌とMET遺伝子異常, RON遺伝子異常

    Type of Award: Other

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2022

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2021

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2020

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2019

Courses Previously Taught 【 Display / hide

  • 内科学、血液ガス、酸塩基平衡

    Keio University

    2015.04
    -
    2016.03

    Autumn Semester, Lecture